Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Viant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scale biology and machine learning. Today, Vyant Bio announced that it has retained Skyline Corporate Communications Group, LLC (“Skyline”) to manage its investor relations and corporate communications activities within the financial community.
Skyline Corporate Communications Group, LLC, with offices in Boston and New York, is an investor relations and corporate communications firm that provides strategic messaging and investor communications consulting services for public companies . Skyline provides strategic assistance to businesses in the capital markets and investment community by helping them effectively communicate their corporate message and competitive advantages.
Jay Roberts, President and CEO of Vyant Bio, said, “Our recent scientific activities, clinical achievements and upcoming clinical milestones have prompted Vyant Bio to select Skyline as its investor relations company. Vyant Bio is developing and bringing significant therapeutic assets into our pipeline that we expect to enhance shareholder value. Vyant Bio believes that Skyline’s strong reputation, communication strategies, methodologies and standards are an excellent match for us as we accelerate clinical discovery and development. Skyline is a knowledgeable partner who will work closely with us to communicate our message to the investing public.
“Vyant Bio is very excited about our expected milestones in 2022 and 2023. We intend to bring our repurposed drug candidate, VYNT-0126 to treat Rett syndrome, into clinical trials in the first half of 2023. Both Vyant Bio’s first new drug candidates, for Rett syndrome and CDKL5, are in the lead discovery phase with our R&D teams and our familial indication of Parkinson’s disease, in collaboration with Organotherapeutics, enters compound screens and improve our modeling of discovery-stage iPSC organoid diseases. Our cutting-edge application of AI technologies and Vyant Bio’s own analytics to interrogate biology through our own machine learning system should enable Vyant to move forward and flag our lead candidates for these two programs at the end of this year as we enter the lead optimization phase. in early 2023,” Mr. Roberts concluded.
Scott Powell, President and CEO of Skyline Corporate Communications Group, LLC, said, “We are very pleased to welcome biotechnology company Vyant Bio to our compelling and growing base of diverse customers. Vyant is entering an exciting phase of discovery and scientific advancement, and we are delighted to provide assistance in effectively and strategically communicating this message to its existing and potential shareholder base, while expanding the company’s awareness within the American financial community.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nadsaq: VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapies. Vyant Bio has built a therapeutic platform aimed at treating neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett syndrome (“Rett”), CDKL5 deficiency disorders (“CDD”) and Parkinson’s disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to reduce candidate screening risks, with the goal of improving the potential efficacy of drugs discovered earlier in the development cycle. Vyant Bio management believes that drug discovery must gradually shift to more efficient methods, as widely used models for predicting safe and effective drugs have underperformed, as evidenced by the significant time and cost to market. market for new drugs. By combining sophisticated data science capabilities with highly functional disease models derived from human cells, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to data assimilation. that supports decision-making iteratively throughout the discovery phase of drug development. to identify both novel and repurposed CNS therapeutic candidates.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements relating to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the effectiveness of our screening and drug discovery process, and the potential for our services, future revenues or growth in this press release constitute forward-looking statements. All statements that are not historical facts (including, but not limited to, statements containing words such as “will”, “believe”, “plan”, “anticipate”, “expect” and “esteem”) must also be taken into account. be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapting to the global coronavirus pandemic, raising capital to meet our liquidity needs, and other risks discussed in Vyant Bio, Inc.’s Form 10-K for the year ended 31 December 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Skyline Business Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 10th Floor
New York, NY 10020 USA
Office: (646) 893-5835 x2
E-mail: [email protected]